文献速递泌尿生殖腹部MR

全自动诊断AI软件在前列腺MRI中的评估:临床评价与组织病理学对照

Assessment of a fully-automated diagnostic AI software in prostate MRI: Clinical evaluation and histopathological correlation.
PubMed 文献 · Eur J Radiol · 2024-10-15

本回顾性研究纳入123例接受多参数前列腺MRI及系统与靶向穿刺活检的患者,以组织病理学为参考标准,评估商用全自动AI软件mdprostate按PI-RADS v2.1识别和分级前列腺病变的诊断效能;该软件在PI-RADS≥2阈值下敏感度100%,在PI-RADS≥4阈值下检测临床有意义前列腺癌的敏感度为85.5%、特异度为63.2%,任何级别癌症的AUC为0.803。

要点

  • PI-RADS≥2阈值下敏感度100%,可有效排除低于该阈值的临床有意义和无意义前列腺癌。
  • PI-RADS≥4阈值下检测临床有意义前列腺癌敏感度85.5%、特异度63.2%。
  • 任何级别癌症检测AUC为0.803,性能与PI-RADS v2.1的两项Meta分析相当。

核心结论

  • 该AI工具在识别和分级前列腺病变方面诊断性能高,结果与专家读者使用PI-RADS v2.1的Meta分析报告相当。
  • 其标准化评估并可能减少变异性的能力,凸显其作为前列腺癌诊断路径中有价值辅助工具的潜力。
  • mdprostate的高准确度,尤其在排除前列腺癌方面,通过减少工作量和改善患者结局体现其临床实用性。

研究设计与样本

  • 回顾性研究,分析123例接受多参数前列腺MRI后行系统与靶向穿刺活检的患者。
  • MRI方案遵循国际指南,包括T2加权、扩散加权、T1加权和动态对比增强成像。
  • AI软件mdprostate整合于图像归档与通信系统,自动分割前列腺、计算前列腺体积,并基于双参数T2加权和扩散加权成像按PI-RADS评分分类病变。
  • 以穿刺活检芯的组织病理学分析为参考标准。

关键影像表现/征象

  • AI软件自动分割前列腺并计算前列腺体积。
  • AI软件基于双参数T2加权和扩散加权成像按PI-RADS评分对病变进行分类。

诊断标准与关键数值

  • PI-RADS≥2阈值下敏感度100%,可有效排除低于该阈值的临床有意义和无意义前列腺癌。
  • PI-RADS≥4阈值下检测临床有意义前列腺癌敏感度85.5%、特异度63.2%。
  • 任何级别癌症检测的AUC为0.803。
  • 与PI-RADS v2.1的两项Meta分析相比,敏感度和特异度无显著差异(p>0.05)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aims to evaluate the diagnostic performance of a commercial, fully-automated, artificial intelligence (AI) driven software tool in identifying and grading prostate lesions in prostate MRI, using histopathological findings as the reference standard, while contextualizing its performance within the framework of PI-RADS v2.1 criteria.

MATERIAL AND METHODS: This retrospective study analyzed 123 patients who underwent multiparametric prostate MRI followed by systematic and targeted biopsies. MRI protocols adhered to international guidelines and included T2-weighted, diffusion-weighted, T1-weighted, and dynamic contrast-enhanced imaging. The AI software tool mdprostate was integrated into the Picture Archiving and Communication System to automatically segment the prostate, calculate prostate volume, and classify lesions according to PI-RADS scores using biparametric T2-weighted and diffusion-weighted imaging. Histopathological analysis of biopsy cores served as the reference standard. Diagnostic performance metrics including sensitivity, specificity, positive and negative predictive value (PPV, NPV), and area under the ROC curve (AUC) were calculated.

RESULTS: mdprostate demonstrated 100 % sensitivity at a PI-RADS ≥ 2 cutoff, effectively ruling out both clinically significant and non-significant prostate cancers for lesions remaining below this threshold. For detecting clinically significant prostate cancer (csPCa) using a PI-RADS ≥ 4 cutoff, mdprostate achieved a sensitivity of 85.5 % and a specificity of 63.2 %. The AUC for detecting cancers of any grade was 0.803. The performance metrics of mdprostate were comparable to those reported in two meta-analyses of PI-RADS v2.1, with no significant differences in sensitivity and specificity (p > 0.05).

CONCLUSION: The evaluated AI tool demonstrated high diagnostic performance in identifying and grading prostate lesions, with results comparable to those reported in meta-analyses of expert readers using PI-RADS v2.1. Its ability to standardize evaluations and potentially reduce variability underscores its potential as a valuable adjunct in the prostate cancer diagnostic pathway. The high accuracy of mdprostate, particularly in ruling out prostate cancers, highlights its clinical utility by reducing workload and enhancing patient outcomes.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Bayerl N, Adams LC, Cavallaro A, et al. Assessment of a fully-automated diagnostic AI software in prostate MRI: Clinical evaluation and histopathological correlation. Eur J Radiol. 2024. PMID: 39520837. doi:10.1016/j.ejrad.2024.111790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。